LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

In Teva Branded Pharm. Prods. R&D v. Amneal Pharms. of N.Y., LLC, the US District Court for the District of New Jersey ordered Teva to delist ...

Although millions of Medicare recipients could see big drug savings in 2025, many insurers plan to raise their premiums. Here ...

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

GE HealthCare (Nasdaq: GEHC) today unveiled CareIntellect for Oncology, a new, cloud-first application utilizing generative ...

A combination of two drugs that can block the growth of cancer cells has shown promising results in women with a form of ...

Pharmacists insist no policies have changed as doctors try to determine why their patients have to chase down medication ...

At the Neurocritical Care Society's (NCS) 22nd Annual Meeting this week, a University of Cincinnati researcher presented ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

Learn how to effectively navigate the challenges of CMC in breakthrough drug development. Discover key strategies here.

The NDA submission for the treatment of presbyopia is supported by the positive data results from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not ...

TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery ...